Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2019
Event: Regulation FD Disclosure regarding an upcoming investor presentation at the BIO CEO & Investor Conference scheduled for February 11, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely as a notice of a forthcoming presentation and does not contain financial statements or operational data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing references an attached investor presentation (Exhibit 99.1) which contains the substantive information to be discussed at the conference.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to discuss information contained in the attached Exhibit 99.1 at the BIO CEO & Investor Conference.
Legal Disclaimer: The information furnished in this 8-K and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act, is not subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filings unless specifically referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for the actual data and strategic updates intended for the February 11, 2019 conference.
- Verify the specific details of the presentation content, as the 8-K text only announces the event.
- Confirm the Company's status as an "Emerging Growth Company" as indicated in the filing.